Article
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Cell - 9 Aug 2018
Rambow Florian, Rogiers Aljosja, Marin-Bejar Oskar, Aibar Sara, Femel Julia, Dewaele Michael, Karras Panagiotis, Brown Daniel, Chang Young Hwan, Debiec-Rychter Maria, Adriaens Carmen, Radaelli Enrico, Wolter Pascal, Bechter Oliver, Dummer Reinhard, Levesque Mitchell, Piris Adriano, Frederick Dennie T, Boland Genevieve, Flaherty Keith T, van den Oord Joost, Voet Thierry, Aerts Stein, Lund Amanda W, Marine Jean-Christophe
Abstract excerpt
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD, we applied single-cell RNA sequencing to malignant cells isolated from BRAF mutant patient-derived xenograft melanoma cohorts exposed to concurrent RAF/MEK-inhibition. We identified distinct...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.